MXCT · Maxcyte, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 12, 2026TL;DR. MaxCyte reported Q2 revenue of $7.3M (-15% YoY) but reiterated 2026 guidance of $30-32M, announced a multi-platform enterprise partnership with Genentech, and cut operating expenses by 25% YoY to $15.8M with net loss narrowing to $8.9M.
- + Announced multi-platform enterprise license partnership with Genentech
- + Reiterated full-year 2026 revenue guidance of $30-32M
- + Operating expenses declined 25% YoY to $15.8M
- + Net loss narrowed to $8.9M from $12.4M YoY
- + SPL royalty revenue grew 150% YoY to $0.8M on Casgevy momentum
- − Total revenue declined 15% YoY to $7.3M
- − Core revenue declined 21% YoY to $6.5M
- − Gross margin compressed to 77% from 82% YoY
- − License revenue fell 30% YoY to $1.8M
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Core business revenue | $8.1M | the third quarter of 2026 | — |
| Strategic Platform License (SPL) Program-related revenue | $1M | the third quarter of 2026 | — |
| Gross margin | 77% | Three Months Ended June 30, 2026 filing | — |
| Core revenue generated from SPL partners as a % of core revenue | 46% | As of June 30, 2026 | — |
| EBITDA | -14.39M | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted Gross Margin non-GAAP | 77% | As of June 30, 2026 | — |
| Non-GAAP Gross Margin non-GAAP | 77% | Six months ended June 30, 2026 | — |
| Total cash, cash equivalents, and investments | $142M | As of June 30, 2026 | — |
| Total Installed Base of Instruments (sold or licensed) | 899 | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MXCT
this stock
Maxcyte, Inc.
|
$147.58M | -5.2% | -14.5% | — | 1.1% |
|
ABT
Abbott Laboratories
|
$171.24B | -19.8% | +5.7% | 31.8 | 0.8% |
|
MDT
Medtronic plc
|
$121.04B | -3.2% | +8.4% | 23.3 | 3.1% |
|
SYK
Stryker Corp
|
$116.76B | -15.3% | +11.2% | 31.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$64.51B | -53.3% | +12.5% | 18.0 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 14, 2026
- This year
- 15
MaxCyte announced preliminary third-quarter 2026 core business revenue of approximately $8.1 million, up 26%, and raised full-year 2026 revenue guidance to approximately $34 million from $30 million to $32 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MXCT | +17.6% | +23.5% | +67.1% | +31.3% | -5.2% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | +17.2% | +22.8% | +59.5% | +29.9% | -18.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.